BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Policy

  City Of Hope, Leading Cancer Research And Treatment Center, To Provide First-Ever FDA-Approved CAR-T Cell Therapy For Adult Patients With Certain Types Of Large B-Cell Lymphoma

  City of Hope will be one of the first authorized centers in the nation to provide axicabtagene ciloleucel, which the U.S. Food and Drug Administration (FDA) announced today is the first approved CAR-T cell therapy.

  October 18, 2017

   · 

  5 min read
• Ampio Announces Closing of Registered Direct Offering

  Ampio today announced that it has closed it’s previously announced registered direct offering of 7,709,400 shares of common stock at a purchase price of $0.875 per share for gross proceeds of approximately $6.75M.

  October 18, 2017

   · 

  3 min read
• 

  Business

  Eli Lilly Strikes $1.8B mRNA R&D Pact With CureVac

  Eli Lilly has signed a collaboration deal with CureVac that could total up to $1.8B.

  October 18, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Alnylam Jumps on $1B RNAi Pact With Vir Biotechnology

  Alnylam and startup Vir Biotech inked a deal worth up to $1B for the development and marketing of RNAi therapies aimed at treating infectious diseases including HBV.

  October 18, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Visterra Inks $1B Deal With This Bay Area Biotech

  Two weeks after securing more than $46M in financing, Visterra struck a deal worth up to $1B with startup Vir Biotech.

  October 18, 2017

   · 

  3 min read

   · 

  Alex Keown
• Business

  Former Eli Lilly Exec Emerges as the Front-Runner for Top HHS Job

  Alex Azar worked at the Department of Health and Human Services under President George W. Bush before joining drugmaker Eli Lilly.

  October 18, 2017

   · 

  1 min read
• 

  Deals

  Shire Under Pressure to Break Up the Business

  Sachem Head Capital Management is pushing for that company to break up into small entities in order to increase shareholder value.

  October 18, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Reckitt to Break Up Company in Restructuring

  The company has decided to split its business into two units - consumer healthcare and home and hygiene products

  October 18, 2017

   · 

  1 min read
• 

  Pharm Country

  This Massachusetts Pharma Doubled Its Market Cap in 2017, What’s Next?

  Vertex has done everything an investor could ask for in 2017, including double its market cap to almost $40B.

  October 18, 2017

   · 

  1 min read
• 

  Biotech Bay

  3 Under-the-Radar Bay Area Biotechs That Could Double in 2018

  Biotech stocks are generally viewed as highly volatile. Of course, along with volatility comes the possibility for huge upside rewards.

  October 18, 2017

   · 

  2 min read

   · 

  Mark Terry